ArticleNature communications2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 44 citations in OpenAlex.
- A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.Blood advances · 2026Trial
- MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.Cancer research communications · 2026Trial
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- Targeting the DNA Damage Response in Cancer.MedComm · 2026Review
- Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.British journal of cancer · 2026Article
- CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- ATR inhibition induces NF-κB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING.NPJ precision oncology · 2026Article
- Targeted inhibition of ATR kinase promotes antitumor immunity in HNSCC through enhanced STING activation and T cell function.Translational oncology · 2026Article
- The DNA damage response and cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial.Oncology and therapy · 2026Article
- PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.The Journal of clinical investigation · 2026Article
- Targeted therapeutic strategies forTranslational lung cancer research · 2026Review
- Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.British journal of cancer · 2026Article
- Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survival.bioRxiv : the preprint server for biology · 2026Article
- ATR kinase inhibitors induce mitochondrial fission in CD8bioRxiv : the preprint server for biology · 2026Article
- Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC.Cell reports. Medicine · 2026Article
- AI-Driven Combination Therapy for Counteracting Dysregulated Genes in Lung Adenocarcinoma: Contribution-Aware Metaheuristic for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Harnessing myeloid cell plasticity for cancer therapy.Nature cancer · 2026Review
- Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC.MedScience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors at 10 institutions in 10 countries.
Elizabeth L Hardaker *Oncology R&D, AstraZeneca, Cambridge, UK.
Emilio Sanseviero *Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Ankur Karmokar *Oncology R&D, AstraZeneca, Cambridge, UK.
Devon Taylor *Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Marta MiloOncology R&D, AstraZeneca, Cambridge, UK.
Chrysis MichaloglouOncology R&D, AstraZeneca, Cambridge, UK.
Adina HughesOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-5711-627X
Mimi MaiOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Matthew KingOncology R&D, AstraZeneca, Cambridge, UK.
Anisha SolankiOncology R&D, AstraZeneca, Cambridge, UK.
Lukasz MagieraOncology R&D, AstraZeneca, Cambridge, UK.
Ricardo MiragaiaOncology R&D, AstraZeneca, Cambridge, UK.
Gozde KarOncology R&D, AstraZeneca, Cambridge, UK.
Nathan StandiferOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.ORCID 0000-0002-9328-1889
Michael SuraceOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Shaan GillOncology R&D, AstraZeneca, Cambridge, UK.
Alison PeterOncology R&D, AstraZeneca, Cambridge, UK.
Sara TalbotOncology R&D, AstraZeneca, Cambridge, UK.
Sehmus TohumekenOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Henderson FryerOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Ali MostafaOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Kathy MulgrewOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Carolyn LamOncology R&D, AstraZeneca, Cambridge, UK.
Scott HoffmannImaging and Data Analytics, AstraZeneca, Cambridge, UK.ORCID 0000-0002-2107-3132
Daniel SuttonImaging and Data Analytics, AstraZeneca, Cambridge, UK.
Larissa CarnevalliOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-7432-0195
Fernando J Calero-NietoOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0003-3358-8253
Gemma N JonesOncology R&D, AstraZeneca, Cambridge, UK.
Andrew J PierceOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-9062-0307
Zena WilsonOncology R&D, AstraZeneca, Cambridge, UK.
David CampbellOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Lynet NyoniOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-5490-2208
Carla P MartinsOncology R&D, AstraZeneca, Cambridge, UK.
Tamara BakerCPSS AST, AstraZeneca, Cambridge, UK.
Gilberto Serrano de AlmeidaCPSS AST, AstraZeneca, Cambridge, UK.
Zainab RamlaouiOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.ORCID 0009-0004-8312-5569
Abdel BidarCPSS, Imaging, AstraZeneca, Gothenburg, Sweden.
Benjamin PhillipsData Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Joseph BolandOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Sonia IyerOncology R&D, AstraZeneca, Boston, MA, USA.ORCID 0000-0003-3840-5583
J Carl BarrettOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Arsene-Bienvenu LoembéEarly Clinical Development, AstraZeneca, Oss, the Netherlands.
Serge Y FuchsDepartment of Biomedical Sciences, School of Veterinary Medicine University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-0136-5103
Umamaheswar DuvvuriUPMC Department of Otolaryngology and UPMC Hillman Cancer Center, 200 Lothrop St. Suite 500, Pittsburg, PA, 15213, USA.
Pei-Jen LouNational Taiwan University Hospital, No. 7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei City, 10002, Taiwan.ORCID 0000-0002-3383-8593
Melonie A NanceVA Pittsburgh Healthcare System, University Drive C, Pittsburg, PA, 15240, USA.
Carlos Alberto Gomez RocaInstitut Claudius Regaud-Cancer Comprehensive Center, 1 Avenue Irene Joliot-Curie, IUCT-O, Toulouse, 31059 Cedex 9, France.ORCID 0000-0002-8043-2529
Elaine CadoganOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-9757-8305
Susan E CritichlowOncology R&D, AstraZeneca, Cambridge, UK.
Steven FawellOncology R&D, AstraZeneca, Boston, MA, USA.
Mark CobboldOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Emma DeanOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-9956-257X
Viia Valge-ArcherOncology R&D, AstraZeneca, Cambridge, UK.
Alan LauOncology R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0003-1055-9812
Dmitry I GabrilovichOncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. dmitry.gabrilovich@astrazeneca.com.ORCID 0000-0001-9913-6407
Simon T BarryOncology R&D, AstraZeneca, Cambridge, UK. simon.t.barry@astrazeneca.com.ORCID 0000-0002-8511-0588
AstraZeneca (United Kingdom) · GBAstraZeneca (Netherlands) · NLAstraZeneca (Brazil) · BRAstraZeneca (Singapore) · SGInstitut Claudius Regaud · FRNational Taiwan University Hospital · TWTempest Technologies (United States) · USUniversity of Pennsylvania · USUPMC Health System · USVA Pittsburgh Healthcare System · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8
Indexed as
CD8-Positive T-LymphocytesIndolesMorpholinesNeoplasmsPyrimidinesSulfonamidesAnimalsAtaxia Telangiectasia Mutated ProteinsB7-H1 AntigenCell Line, TumorDisease Models, AnimalHumansImmunotherapyMiceTumor MicroenvironmentAtaxia Telangiectasia Mutated ProteinsATR protein, humanB7-H1 AntigenceralasertibIndolesMorpholinesPyrimidinesSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.